Atelerix Life Sciences is developing ATLX-0199, a proprietary small molecule that reverses opioid-induced respiratory depression (OIRD) while preserving analgesic effects. This addresses the critical issue of OIRD in surgical patients, which often leads to prolonged mechanical ventilation and extended hospital stays.
Funding
$650K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Opioid-induced respiratory depression (OIRD) is a common and potentially deadly side effect of opioid use, particularly in post-surgical patients, often leading to prolonged mechanical ventilation and extended hospital stays. Current treatments like Naloxone reverse OIRD but also negate the analgesic effects of the opioids, causing patients to experience pain breakthrough. This necessitates a solution that restores breathing without sacrificing pain relief.
Solution
Atelerix Life Sciences is developing ATLX-0199 (Sudaxine), a proprietary small molecule designed to reverse opioid-induced respiratory depression (OIRD) while preserving the analgesic effects of the opioid. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia. Pre-clinical in-vitro and in-vivo data demonstrate that ATLX-0199 increases minute ventilation and overcomes opioid-induced respiratory depression without negatively impacting the analgesic actions of morphine. The compound has demonstrated overall chemical stability, efficacy, negligible cardiovascular effects, and favorable onset profiles.
Target Audience
The primary target audience includes hospitals, surgical centers, and medical professionals treating patients at risk of opioid-induced respiratory depression, specifically post-surgical patients requiring pain management.
Features
- Proprietary small molecule platform targeting OIRD
- Reverses respiratory depression induced by opioids
- Preserves opioid-induced analgesia, preventing pain breakthrough
- Demonstrated efficacy in pre-clinical in-vitro and in-vivo studies
- Increases minute ventilation and overcomes V/Q mismatch
- Exhibits chemical stability and negligible cardiovascular effects